What is it?
One core compound, different salts
1Emoxypine is the free-base identity behind a family of salts. The index includes succinate products and the malate product Ethoxidol; their brand names, dose numbers and clinical evidence are not interchangeable.
Positive cognitive findings are clinical
3A 2024 meta-analysis pooled ten prospective studies in chronic brain ischemia with cognitive impairment: 482 participants receiving Mexidol and 455 comparators. The average MoCA difference favored Mexidol by 2.06 points. This clinical-scale result does not establish healthy-adult memory enhancement or a shared effect across salt forms.
The MEMO regimen was not oral-only
4MEMO randomized 318 adults aged 40-90 with chronic brain ischemia to sequential intravenous then oral Mexidol or matching placebo. MoCA and several secondary scales favored Mexidol. Those findings apply to the whole monitored regimen, not to an isolated retail tablet or healthy-adult use.
Null cognitive results also matter
6A 60-person rehabilitation study found no significant between-group MoCA difference despite selected favorable mood and mobility outcomes. No adverse events were recorded, but that small study cannot establish absence of harm. Positive results in one domain should not become a general cognition claim.
Newer stroke data are not a nootropic trial
7The 2025 MIR study randomized 304 stroke patients to injections followed by tablets or placebo. Disability and several neurological measures favored Mexidol; the abstract describes cognition only as a trend. It does not show that oral emoxypine improves cognition in healthy adults.
Research transparency has limits
5The MEMO registry names Pharmasoft as sponsor. The study finished in 2020, while this ClinicalTrials.gov record was first posted in 2025. A later registry entry cannot serve as prospectively registered evidence, and subgroup reports should not be counted as independent trials.
Names, aliases and forms
Mechanisms of action
A mechanism is not an outcome
8A recent review discusses antioxidant, membrane and succinate-signaling pathways. These pharmacological proposals are useful research context, but do not demonstrate better focus, stress resilience or long-term brain protection in healthy people.
Potential effects and evidence map
Grade C reflects positive but population-specific human findings, alongside null cognitive comparisons. A meta-analysis and the MEMO trial concern clinical impairment, not everyday performance in healthy adults. Mixed injection/tablet regimens and salt differences limit transfer to retail oral products.
Some clinical cognitive scores favor Mexidol; benefits for healthy-adult memory or learning remain unestablished.
No validated acute focus or attention benefit is established for healthy adults.
Selected mood scales improved in a small rehabilitation study, alongside a null cognitive comparison.
Antioxidant and membrane mechanisms explain research interest, not proven long-term brain protection.
Typical dosages and timing
The trial used 250 mg three times daily for 60 days after a 14-day intravenous phase. The displayed amount is oral succinate research exposure, not an oral-only result, a malate equivalent or a recommended healthy-adult regimen.
Timing & effect horizon
The displayed The time for blood levels to fall by half during the final elimination phase.Source comes from oral Mexidol product information. It measures elimination, not onset or duration of improved cognition. Malate has its own formulation-specific pharmacokinetics; do not use one salt's timing to schedule another.
Safety, side effects and risk profile
U.S. substance identifiers do not establish approval or legal import of a finished product.
Patient trials do not quantify long-term healthy-adult safety or validate an enhancement dose.
Ethoxidol labeling flags enhanced effects of several CNS medicines and cardiovascular drugs.
Longer Ethoxidol use can involve drowsiness or difficulty falling asleep.
Ethoxidol labeling describes rare nausea, dry mouth, diarrhea or digestive discomfort, usually reversible.
Ethoxidol is contraindicated in pregnancy and breastfeeding because safety studies are inadequate.
The oral Mexidol label lists very rare angioedema, hives, drowsiness, headache, digestive and skin reactions. These are label frequencies, not a measured healthy-user rate. Breathing difficulty or facial/throat swelling needs urgent medical attention.
Interactions and cautions
Oral Mexidol labeling notes enhanced effects of benzodiazepines, antidepressants, anxiolytics, anticonvulsants and Parkinson medicines. Do not interpret general compatibility wording as a guarantee for every combination.
A 2026 analysis of 454 participants from two stroke trials found no significant adverse-event interaction signal for the studied concomitant medicines. That is reassuring within those regimens, not proof that every sedative, supplement stack or malate product is compatible.
Ethoxidol labeling also flags nitrates, ACE inhibitors and beta blockers. Its cautions should be assessed against the actual medication list, not borrowed wholesale from succinate studies.
Legal and regulatory status
As reviewed October 12, 2026, the United States FDA substance registry identifies emoxypine succinate but explicitly separates identifiers from regulatory approval. That record cannot establish lawful marketing or import of a finished product. Requirements differ by destination and product category.
As reviewed October 12, 2026, Russian oral Mexidol information labels it prescription-only. That does not establish United States FDA approval or a worldwide legal status.
How it compares
Ethoxidol declares malate as its active ingredient and also contains deanol, glycine and other excipients. It is a distinct chewable formulation, not a milligram-for-milligram replacement for a Mexidol succinate tablet.
Practical buying and quality notes
- Start with succinate versus malate, then check formulation, strength and pack count. A lower per-tablet price does not prove equal active-moiety exposure or equal clinical benefit. Confirm the selected merchant pack before checkout; product titles can list more than one size.2
- Check the original ingredient label, lot and expiry, and whether the seller supplies the stated oral formulation. Chemical identifiers identify substances, not the authenticity or approval of a particular package. A tablet count should not be confused with milligrams of powder.2
FAQ
What emoxypine dose is supported for healthy adults?
4No validated enhancement dose follows from these studies. The research amount above belongs to succinate after intravenous exposure. Tablet strength is not a daily dose, and copying it to malate or an unspecified powder changes the evidence context.
How long does it last, and is cycling supported?
5Plasma half-life is not the duration of a cognitive benefit. The oral study phase is not an evidence-based consumer cycle. No healthy-adult cycling or redosing schedule is established by the MEMO trial.
References
- PubChem. Emoxypine free-base identity, CID 114681.
- U.S. FDA Substance Registration System. Emoxypine succinate, UNII 2R985002CT.
- Zakharov VV, Vakhnina NV. The use of Mexidol in patients with mild (moderate) cognitive impairment: results of a meta-analysis. 2024;124(1):82-88.
- Fedin AI, et al. Results of the randomized, double-blind, placebo-controlled MEMO study of sequential Mexidol and Mexidol FORTE 250. 2021;121(11):7-16.
- ClinicalTrials.gov. NCT06834490: MEMO study record and posted results.
- Belkin AA, et al. Cohort single-center randomized study of Mexidol in rehabilitation after acute cerebral insufficiency. 2024;124(4):108-117.
- Shamalov NA, et al. Results of the randomized, double-blind, placebo-controlled MIR trial of sequential ethylmethylhydroxypyridine succinate after ischemic stroke. 2025.
- Voronina TA, et al. Known and new ideas about the mechanism of action and spectrum of effects of Mexidol. 2025;125(5):22-33.
- Mexidol manufacturer. Russian Federation product characteristics and leaflet for oral Mexidol 125 mg film-coated tablets. Accessed October 12, 2026.
- Valenta Pharm. Ethoxidol 100 mg chewable-tablet medical-use instructions, Russian registration LP 002227.
- Shikh EV, et al. Drug-drug interactions with Mexidol in patients with ischemic stroke: analysis of randomized clinical trial data. 2026;126(3):141-154.